Journal Watch · Journal for ImmunoTherapy of Cancer · 2026

Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.

Explorative translational research is needed to identify possible biomarkers of response to immunotherapy with ICIs in mCRPC.<h4>Trial registration numbers</h4>European Union Clinical Trial Registry (https://www.clinicaltrialsregister.eu) EudraCT number: 2018-003461-34 and on https://clinicaltrials.gov (NCT05655715).

Eefsen RL, Spindler NJ, Theile S et al.Journal for ImmunoTherapy of Cancer4 min readPharma relevance 85/100

DOI: 10.1136/jitc-2026-014803PMID: 42493213Study type: randomised / controlled clinical trial

TL;DR

Explorative translational research is needed to identify possible biomarkers of response to immunotherapy with ICIs in mCRPC.<h4>Trial registration numbers</h4>European Union Clinical Trial Registry (https://www.clinicaltrialsregister.eu) EudraCT number: 2018-003461-34 and on https://clinicaltrials.gov (NCT05655715).

Key findings

  • Median OS was 10.2 months (95% CI 7.1 to 15.2) in arm A and 9.2 months (95% CI 7.1 to 14.4) in arm B.
  • Treatment-related adverse events grade 3-4 were observed in 27 patients (33.3%).<h4>Conclusions</h4>The addition of SBRT to nivolumab and ipilimumab did not improve outcomes; however, a fraction of the patients had a response to the treatment combination of nivolumab and ipilimumab.
  • Explorative translational research is needed to identify possible biomarkers of response to immunotherapy with ICIs in mCRPC.<h4>Trial registration numbers</h4>European Union Clinical Trial Registry (https://www.clinicaltrialsregister.eu) EudraCT number: 2018-003461-34 and on https://clinicaltrials.gov (NCT05655715).

Numbers at a glance (from the abstract)

21.6%95%9.8%38.2%20.5%35.3%16.7%4.7%37.4%22.2%10.1%39.2%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

The dual primary endpoints in the study were prostate-specific antigen (PSA) response rate and objective response rate (ORR). Secondary endpoints included overall survival (OS), PSA, radiologic progression-free survival, and toxicity.<h4>Results</h4>We enrolled 91 patients, and 81 patients received at least one treatment with ICIs and were eligible for evaluation of the efficacy and safety endpoints. Of the evaluable patient population, the confirmed PSA response rate was 21.6% (95% CI 9.8% to 38.2%) in arm A, and 20.5% (95% CI 9.8% to 35.3%) in arm B. ORR was 16.7% (95% CI 4.7% to 37.4%) and 22.2% (95% CI 10.1% to 39.2%) in arms A and B, respectively.

Full abstract (original)

Background: <h4>Background</h4>Metastatic castration-resistant prostate cancer (mCRPC) is among the leading causes of cancer-related mortality in men worldwide. Treatment options for mCRPC typically include chemotherapy and androgen receptor pathway inhibitors. Immune checkpoint inhibitors (ICIs) have demonstrated a limited effect in mCRPC. We hypothesized that the addition of stereotactic body radiation therapy (SBRT) could enhance immune responses and improve treatment outcomes.<h4>Methods</h4>Patients with mCRPC who had received at least two prior lines of therapy were randomized 1:1 to receive SBRT with nivolumab and ipilimumab (arm A) or nivolumab and ipilimumab (arm B).

What they did: The dual primary endpoints in the study were prostate-specific antigen (PSA) response rate and objective response rate (ORR). Secondary endpoints included overall survival (OS), PSA, radiologic progression-free survival, and toxicity.<h4>Results</h4>We enrolled 91 patients, and 81 patients received at least one treatment with ICIs and were eligible for evaluation of the efficacy and safety endpoints. Of the evaluable patient population, the confirmed PSA response rate was 21.6% (95% CI 9.8% to 38.2%) in arm A, and 20.5% (95% CI 9.8% to 35.3%) in arm B. ORR was 16.7% (95% CI 4.7% to 37.4%) and 22.2% (95% CI 10.1% to 39.2%) in arms A and B, respectively.

Results & conclusions: Median OS was 10.2 months (95% CI 7.1 to 15.2) in arm A and 9.2 months (95% CI 7.1 to 14.4) in arm B. Treatment-related adverse events grade 3-4 were observed in 27 patients (33.3%).<h4>Conclusions</h4>The addition of SBRT to nivolumab and ipilimumab did not improve outcomes; however, a fraction of the patients had a response to the treatment combination of nivolumab and ipilimumab. Explorative translational research is needed to identify possible biomarkers of response to immunotherapy with ICIs in mCRPC.<h4>Trial registration numbers</h4>European Union Clinical Trial Registry (https://www.clinicaltrialsregister.eu) EudraCT number: 2018-003461-34 and on https://clinicaltrials.gov (NCT05655715).

Abstract © the authors / Journal for ImmunoTherapy of Cancer (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1136/jitc-2026-014803 · PubMed 42493213.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Journal for ImmunoTherapy of Cancer study find?

Explorative translational research is needed to identify possible biomarkers of response to immunotherapy with ICIs in mCRPC.<h4>Trial registration numbers</h4>European Union Clinical Trial Registry (https://www.clinicaltrialsregister.eu) EudraCT number: 2018-003461-34 and on https://clinicaltrials.gov (NCT05655715).

What type of study is this?

It is a randomised / controlled clinical trial, published in Journal for ImmunoTherapy of Cancer in 2026. The dual primary endpoints in the study were prostate-specific antigen (PSA) response rate and objective response rate (ORR).

Where can I read the original paper?

The original is at the publisher via DOI 10.1136/jitc-2026-014803. PubMed ID: 42493213. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Eefsen RL, Spindler NJ, Theile S et al.. Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.. Journal for ImmunoTherapy of Cancer (2026). DOI: 10.1136/jitc-2026-014803.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/randomized-phase-ii-trial-of-nivolumab-and-ipilimumab-with-or-without-st-014803/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides